I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Switzerland

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Neuroscience Parkinson's Disease

Parkinson's Disease

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Apr 5 / Roche and Genentech
Two-year progression of walking and turning in daily life of early Parkinson’s disease participants: exploratory findings from the prasinezumab PASADENA study
This presentation explores the two-year progression of passively monitored (PM) motor behaviors in early PD using smartphone sensor data from the PASADENA study. The walking and turning PM features evidenced high reliability, correlations with relevant clinical measures, detected disease progression and progressed numerically less in the group receiving prasinezumab. These results suggest that exploratory PM measures are a valuable tool for monitoring of motor behavior of PD patients during during daily life.
Neuroscience Parkinson's Disease ADPD-2025

Sign up or login to unlock the full suite of MEDICALLY features
Apr 5 / Roche and Genentech
Progression of remotely smartphone-collected voice impairments in early Parkinson’s disease: exploratory results from the PASADENA study of prasinezumab
This presentation of exploratory, post-hoc results from the Pasadena study explores the use of remotely smartphone-collected voice data to track voice impairement progression in early stages of PD. Acoustic measures demonstrated test-retest reliabilty, were sensitive to changes in voice over time and evidenced numerically less progression in the group receiving Prasinezumab. These findings suggest remotely collected voice features are valuable tools for monitoring PD progression.
Neuroscience Parkinson's Disease ADPD-2025

Sign up or login to unlock the full suite of MEDICALLY features
Apr 5 / Roche and Genentech
A PHASE 1B STUDY TO TEST THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SELNOFLAST IN EARLY-STAGE PARKINSON’S DISEASE: STUDY DESIGN AND BASELINE CHARACTERISTICS
Here, we describe the Phase 1b study design and the baseline characteristics of the participants with early-stage PD enrolled in the study to test the safety, pharmacokinetics, and pharmacodynamics effects of selnoflast, a novel NLRP3 inflammasome inhibitor.
Neuroscience Parkinson's Disease ADPD-2025
Treatment Management Research advancements
  • Parkinson's Disease
1 results

Sign up or login to unlock the full suite of MEDICALLY features
Mar 16 / Roche
ADPD 2022 booth slides: Roche in Parkinson’s disease (PD)
Roche are committed to changing the future of people living with PD by looking at multiple targets and developing innovative solutions to slow disease progression. This interactive slide deck presents an overview of PD and highlights Roche’s involvement in tackling the disease, including a summary of the mechanisms of disease that Roche target and an outline of their ongoing studies.
Neuroscience Parkinson's Disease ADPD-2022

Disease Education

Understanding Parkinson's disease

Parkinson's disease is a neurological condition that affects the brain and other parts of the nervous system. The gradual loss of nerve cells leads to a suite of characteristic motor and non-motor symptoms. What causes these cells to die and how the pathology develops in the nervous system are not yet clear but multiple lines of investigation are being pursued to answer these questions. In this animation, we explore some of the latest in Parkinson's disease research.

Watch the video
Open asset
Share page

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.